Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
16 Junio 2023 - 8:05AM
Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)
(“Clearmind” or the "company"), a biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major under-treated health problems, today announced that
as part of the Company's ongoing collaboration with SciSparc Ltd.
(NASDAQ: SPRC) ("SciSparc"), a specialty clinical-stage
pharmaceutical company focusing on the development of therapies to
treat disorders of the central nervous system, it has entered into
a research agreement with the Hebrew University of Jerusalem, to
evaluate Clearmind's and SciSparc's combination treatment for
obesity and metabolic syndrome.
Professor Joseph (Yossi) Tam, D.M.D.,
Ph.D., the Head of the Obesity and Metabolism Laboratory and the
Director of the Multidisciplinary Center for Cannabinoid Research
at the Hebrew University of Jerusalem, will lead the study using
the proprietary combination of Clearmind's MEAI and SciSparc's
PEA.
"We are excited to further investigate the effect
of the combination of MEAI and PEA for treating obesity and
metabolic syndrome. Previous pre-clinical studies performed with
our proprietary MEAI showed a very positive effect in treating
obesity. In this study we want to further investigate the
synergistic effect between our MEAI and SciSparc’ s PEA," said
Clearmind’s Chief Executive Officer, Dr. Adi Zuloff-Shani. "The
collaboration with SciSparc has already yielded numerous patent
applications related to combination therapies for treating binge
behaviors, cocaine addiction, depression and more."
The upcoming study will evaluate the effect of the
combination of MEAI and PEA on food intake, metabolic and activity
profiles.
A previous pre-clinical study, conducted at the
Hebrew University of Jerusalem, under the leadership of Prof. Tam,
as part of a collaboration established with the university’s
technology transfer company, Yissum, included multi-parameter
metabolic assessments such as body weight, fat mass, glucose
tolerance, insulin sensitivity, liver enzymes and fat accumulation,
as well as food consumption patterns. The study included three
groups of rodents: lean rodents that were fed a standard diet,
obese rodents that were fed a high-fat diet, and obese rodents that
were fed a high-fat diet along with MEAI treatment.
Results showed that the obese animals treated with
MEAI demonstrated an increased energy expenditure, as well as
better fat utilization and weight loss of 20%, while reducing their
overall fat mass and preserving lean body mass. No effect on
motivation and well-being was observed. Additionally, MEAI
treatment yielded normalization of insulin levels, improved glucose
tolerance, as well as reduced fat and triglyceride accumulation in
the liver. These results were significantly better than those
obtained in the high-fat, untreated group.
Furthermore, a significant reduction in sucrose
preference was observed following administration of MEAI for two
days, supporting the notion that it can dampen the hedonic value of
rewarding stimuli. Thus, MEAI may be beneficial for the treatment
of compulsive reward-seeking behavior or excessive consumption of
sweet foods.
About Clearmind Medicine
Inc.
Clearmind is a psychedelic pharmaceutical biotech
company focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The company’s intellectual portfolio currently
consists of fourteen patent families. The company intends to seek
additional patents for its compounds whenever warranted and will
remain opportunistic regarding the acquisition of additional
intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on
Nasdaq and the Canadian Securities Exchange under the symbol "CMND"
and the Frankfurt Stock Exchange under the symbol “CWY.”
About SciSparc
Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. SciSparc’s focus is on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the Company is currently engaged
in the following drug development programs based on THC and/or
non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of
Tourette Syndrome, for the treatment of Alzheimer's disease and
agitation; SCI-160 for the treatment of pain; and SCI-210 for the
treatment of autism spectrum disorder and status epilepticus. The
Company also owns a controlling interest in a subsidiary whose
business focusses on the sale of hemp-based products on the
Amazon.com marketplace.
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relationsinvest@clearmindmedicine.comTelephone: (604)
260-1566US: CMND@crescendo-ir.com
General
InquiriesInfo@Clearmindmedicine.comwww.Clearmindmedicine.com
Forward-Looking
Statements:
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses collaboration with
SciSparc and its intent to further investigate the effect of the
combination of MEAI and PEA for treating obesity and metabolic
syndrome. Forward-looking statements are not historical facts, and
are based upon management’s current expectations, beliefs and
projections, many of which, by their nature, are inherently
uncertain. Such expectations, beliefs and projections are expressed
in good faith. However, there can be no assurance that management’s
expectations, beliefs and projections will be achieved, and actual
results may differ materially from what is expressed in or
indicated by the forward-looking statements. Forward-looking
statements are subject to risks and uncertainties that could cause
actual performance or results to differ materially from those
expressed in the forward-looking statements. For a more detailed
description of the risks and uncertainties affecting the Company,
reference is made to the Company’s reports filed from time to time
with the Securities and Exchange Commission (“SEC”), including, but
not limited to, the risks detailed in the Company’s annual report
on Form 20-F filed with the SEC on February 6, 2023.
Forward-looking statements speak only as of the date the statements
are made. The Company assumes no obligation to update
forward-looking statements to reflect actual results, subsequent
events or circumstances, changes in assumptions or changes in other
factors affecting forward-looking information except to the extent
required by applicable securities laws. If the Company does update
one or more forward-looking statements, no inference should be
drawn that the Company will make additional updates with respect
thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release. Clearmind is not
responsible for the contents of third-party websites.
Clearmind Medicine (NASDAQ:CMND)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Clearmind Medicine (NASDAQ:CMND)
Gráfica de Acción Histórica
De May 2023 a May 2024